Thymmune Therapeutics is a preclinical biotechnology company based in Cambridge, MA applying proprietary insights in thymic engineering to develop and commercialize immune cell therapy products addressing significant opportunities with unmet clinical need across immunology. Building on work from leading labs, Thymmune has strong IP positioning and is backed by early investors and founders of successful high-profile biotechnology companies.